250/50 (fluticasone propionate 250 mcg and salmeterol 50 mcg inhalation powder)
Material Safety Data Sheets Environmental Risk Assessments45/21, 115/21, 230/21 (fluticasone propionate 45 mcg, 115 mcg, 230 mcg and salmeterol 21 mcg) Inhalation Aerosol
Material Safety Data Sheets Environmental Risk Assessments(umeclidinium 62.5 mcg and vilanterol 25 mcg inhalation powder)
Material Safety Data Sheets Environmental Risk Assessments(fluticasone furoate inhalation powder) 100 mcg and 200 mcg
Material Safety Data Sheets Environmental Risk Assessments(beclomethasone dipropionate, monohydrate) Nasal Spray, 42 mcg
Material Safety Data Sheets Environmental Risk Assessments(fluticasone furoate 100 mcg and vilanterol 25 mcg inhalation powder)
Material Safety Data Sheets Environmental Risk Assessments50 mcg/100 mcg/250 mcg (fluticasone propionate inhalation powder, 50 mcg/100 mcg/250 mcg)
Material Safety Data Sheets Environmental Risk AssessmentsHFA 44 mcg/110 mcg/220 mcg (fluticasone propionate 44 mcg/110 mcg/220 mcg) Inhalation Aerosol
Material Safety Data Sheets Environmental Risk Assessments(umeclidinium 62.5 mcg inhalation powder)
Material Safety Data Sheets Environmental Risk Assessments(mepolizumab) for injection, for subcutaneous use
Material Safety Data Sheets Environmental Risk Assessments(salmeterol xinafoate inhalation powder)
Material Safety Data Sheets Environmental Risk Assessments(fluticasone furoate, umeclidinium, and vilanterol inhalation powder)
Material Safety Data Sheets Environmental Risk Assessments(albuterol sulfate) Inhalation Aerosol
Material Safety Data Sheets Environmental Risk Assessments(fluticasone furoate) Nasal Spray
Material Safety Data Sheets Environmental Risk AssessmentsPresented by: Dr. Michael E. Wechsler, MD, MMSc
Blood Eosinophil Unit Conversion Calculator
American Academy of Allergy, Asthma & Immunology
American Association for Respiratory Care
American College of Allergy, Asthma & Immunology
American College of Chest Physicians
Centers for Disease Control and Prevention Asthma Information
Centers for Disease Control and Prevention COPD Information
Global Initiative for Chronic Obstructive Lung Disease
Nov 13-15, 2020 | Virtual
Oct 18-21, 2020 | Virtual
Aug 5-10, 2020 | Virtual
Mar 13-16, 2020 | Philadelphia, PA (Cancelled due to COVID-19)